Superworth

Revvity price to book ratio RVTY

Market value divided by the book value of the company's net assets, since 2010.

Today, Oct 23, 2026
2.5×
10-year median
2.9×
Against its 10-year history
40th
percentile: 0 is its lowest day, 100 its highest
10-year range
1.3× to 5.5×
Peer median
7.5×

Revvity's price to book ratio is 2.5× as of Oct 23, 2026.

That is below its ten-year median of 2.9×, close to the middle of its last ten years.

Over that time it ranged from 1.3× in Sep 2025 to 5.5× in Jan 2021.

The median for 10 diagnostics and research stocks of a similar size is 7.5×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far2.5×1.3×2.5×
20251.5×1.3×1.9×
20241.7×1.6×2.0×
20231.8×1.4×2.5×
20222.5×2.1×3.3×
20213.6×3.3×5.5×
20205.0×2.8×5.3×
20194.0×3.3×4.3×
20183.3×3.2×4.3×
20173.2×2.7×3.5×
20162.7×2.4×3.0×
20152.9×2.4×3.0×
20142.4×2.2×2.7×
20132.4×1.8×2.4×
20121.8×1.2×1.9×
20111.2×1.0×1.9×
20101.8×1.5×1.8×

Against its peers

Companies in Medical - Diagnostics & Research nearest Revvity's size, closest first, today.

CompanyPrice to book ratio
RVTYRevvity2.5×
MEDPMedpace43.1×
LHLabcorp3.1×
DGXQuest Diagnostics3.6×
BIOBio-Rad Laboratories1.4×
MTDMettler-Toledo Internationaln/m
CAICaris Life Sciences15.3×
ILMNIllumina14.3×
IDXXIDEXX Laboratories27.4×
WATWaters2.9×
IQVIQVIA7.5×
Peer median7.5×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Revvity

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.